We explored the gene expression in colonic biopsies of active and inactive inflammatory bowel disease (IBD), in an extensive material of ulcerative colitis (UC) and Crohn`s disease (CD). The chemokine CXCL10 and its receptor CXCR3 were among the upregulated genes.
Introduction
Chemokines direct the recruitment and migration of circulating leukocytes to inflammatory sites, and are important for the differentiation of secondary lymphoid tissue. They can be produced locally, by resident cells or by infiltrating leucocytes. The chemokines determine the composition of leukocytes in inflammation, and are thus central factors in the perpetuation of the inflammatory process (1).
In active ulcerative colitis and Crohn`s disease the immunological homeostasis is broken and the mucosa is characterized by influx of both innate immune cells (neutrophils,
macrophages, dendritic cells and natural killer T-cells) and the adaptive immune cells (B-cells and T-cells). The balance/composition of subgroups of T-cells, especially Th1, Th2, Th17 and
Treg, has been of particular interest (2) (3) (4) . One highly relevant chemokine in this context is CXCL10 (formerly IP-10: interferon-γ induced protein 10).
CXCL10 is a typical CXC-chemokine where two of the four cysteine (C) residues that are located at the N-terminal part of the protein are separated by one amino acid (X). CXCL10 is a ligand for the receptor CXCR3, which is also the case for CXCL9 (former MIG) and CXCL11 (former I-TAC). Binding of ligand to CXCR3 is crucial for chemotaxis of these receptor positive cells to inflammatory sites (5) . CXCL10 is regarded as a chemoattractant preferentially for activated T-cells (6) and particularly Th1 cells (7) .
In a large-scale microarray study on endoscopic biopsies from diseased and nondiseased colon of UC and CD patients compared to healthy colonic mucosa from control individuals, we found a markedly enhanced and highly significant upregulation of CXCL10 mRNA and also a more modest overexpression of the CXCR3 receptor. Bearing in mind the central role of the innate immune system in these diseases we carried out a series of studies on CXCL10 expression in a patient material and in colon-derived intestinal cell lines with a panel of pattern recognition receptor-ligands covering the toll-like receptors (TLR) 1-9, nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and the cytokines IL10 and IL1β, to explore the sources and regulation of CXCL10.
Materials and methods

Clinical material
Patients admitted to the Gastrointestinal Endoscopy Unit, Department of Gastroenterology and Hepatology, St. Olav's University Hospital, were included in the study.
The patients had ulcerative colitis or Crohn's disease, or underwent colonoscopy due to gastrointestinal symptoms. Healthy controls were included among those who had colonoscopy with normal macro-and microscopic findings, and where clinically indicated supplementary examination did not reveal any significant disease. The UC group also included patients with associated primary sclerosing cholangitis (PSC). Patients using immunomodulants such as azathioprine or TNF alpha blockers were excluded. Colonoscopic biopsies were collected from macroscopically maximally inflamed colonic mucosa, normal biopsies always from the hepatic flexure. Four adjacent biopsies were taken from each location and either snap frozen and stored on liquid nitrogen, or fixed in 4% buffered formaldehyde. Hematoxylin-eosin stained sections were examined by an experienced pathologist to verify the presence or absence of inflammation. Serum was stored at -80 o C and used for analysis of chemokines and high-sensitivity CRP (hsCRP). PBMCs were obtained from heparinized peripheral venous blood by centrifugation (800g for 20 min at room temp.) on Lymphoprep mononuclear cell separation medium (Axis-Shield, Oslo, Norway) and stored in liquid nitrogen.
Ethical considerations
The study was approved by the Regional Medical Research Ethics Committee, and was registered in the Clinical Trials Protocol Registration System (identifier NCT00516776). All patients and control individuals gave informed consent.
Gene expression analysis
Microarray gene expression analysis was done on 133 colonic biopsies. Frozen biopsies were homogenized, and RNA extracted using the Ambion mirVana mRNA isolation kit (Ambion, Austin, TX). Total RNA quantity and quality was assessed using NanoDrop Spectrophotometer (Thermo Scientific, Stockholm, Sweden) and Bioanalyzer capillary electrophoresis (Agilent Technologies, Santa Clara, CA). All RNA samples were of high quality (RIN > 7). Microarray analysis was performed using Illumina human HT-12 expression BeadChips (Illumina, San Diego, CA) on an Illumina BeadStation.
Histological and Immunhistochemical examination
Formaldehyde-fixed colonic biopsies were embedded in paraffin, and 4 µm sections cut and prepared for histological and immunohistochemical examination. Biopsies were stained with hematoxylin-eosin and evaluated by an expert pathologist assessing inflammation. The samples were classified as "normal", "chronic inflammation" or "chronic active inflammation", based on mucosal mononuclear and neutrophilic cellular infiltration, respectively.
The same biopsies were further used for immunohistochemistry. For CXCL10 / CXCR3 immunohistochemistry, five sections from each of the sample groups active UC (UCa), inactive UC (UCi) active CD (CDa) inactive CD (CDi) and controls (C) were stained.
These commercially available antibodies were used: CXCL10 goat polyclonal antibody (cat.
nr. AF-266-NA, R&D Systems, Minneapolis, MN) dilution 1:5, CXCR3 mouse monoclonal antibody (cat. nr. ab64714. Abcam plc, Cambridge, UK) dilution 1:250). Detection was done using Dako EnVision peroxidase kit and Dako DAB+ chromogen (Dako, Glostrup, Denmark). Sections were counterstained with hematoxylin. For CXCL10, the degree of staining of the epithelium was assessed by two independent examiners as "no to little"=0 or "moderate to strong"=1. CXCR3 was quantified by counting positive cells in 4 different fields pr. slide (magnification x40). If total number positive cells for a sample was below the median for all samples, it was denoted 0, if above the median then denoted 1, then tested using Fischer Exact Test.
Culture and stimulation of intestinal epithelial cells
Two intestinal epithelial cell lines were used; HT-29 from a human colorectal adenocarcinoma, and SW620, from a lymph node metastasis of a human colorectal adenocarcinoma (Cat.nr. HTB-38 and CCL227, ATCC Manassas, VA). The cells were cultured at 37°C, 5% CO 2 in RPMI supplemented with fetal bovine serum 10%, glutamine 2mM and gentamicin 0.05%. They were detached from the culture flasks using trypsin/EDTA, resuspended in medium, and counted in a Countess Automated Cell Counter (Life Technologies, Grand Island, NY). Stimulation experiments were done in triplicate with 20000 cells per well in 96-well, flat-bottom plates incubated overnight at 37°C, 5% CO 2 . Medium was then removed and fresh medium or TLR-ligand/cytokine was added. The ligands, target receptor in parenthesis, were the lipopeptide Pam3CysSK4(P3C) (TLR2/1), 300ng/mL, Lipomannan (LM) (TLR2/6), 30ng/mL, synthetic double-stranded RNA mimic, polyinosinic: polycytidylic acid (poly(I:C)) (TLR3), 50µg/mL , lipopolysaccharide (LPS) (TLR4), 100ng/mL , Flagellin (TLR5), 100ng/mL, the antiviral compound R848 (TLR7/8), 100ng/mL (all from InvivoGen, Toulouse, France), unmethylated CpG dinucleotides (TLR9), 10 μM (TibMolBiol, Berlin, Germany), the peptidoglycan component muramyl dipeptide (MDP) (NOD2) 1µg/mL (InvivoGen, Toulouse, France), and the recombinant cytokines IL-10, 100ng/mL , IL-1β, 100ng/mL (both from PeproTech, Rocky Hill, NJ). The cells were incubated at 37°C, 5% CO 2 for 20h before supernatant was harvested and stored at -20°C. CXCL10 in supernatans was quantified using an ELISA human Duo-Set (R&D, Abigdon, UK) according to manufactures instruction..
The viability of cells was determined by a colorimetric method; the MTT-(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Promega, Nacka, Sweden) (0.5mg/ml) in 10%FCS/RPMI was added to the adherent cells and incubated at 37°C, 5% CO for 3 hours. Supernatants were replaced by alkaline isopropanolol with 0.25% 1M NH 3 OH.
The plate was stirred for 30 min and optical density was measured at 570 nm using the luminometer function of Walla Victor3 TM 1420 Multilabel Counter by Perkin Elmer TM .
.
TLR3 siRNA transfection of the intestinal epithelial cell line HT-29.
HT-29 cells were detached by trypsination and seeded at 20000 cells per well using culture medium without antibiotics. Transfection took place initially after plating cells using the transfection agent Lipofectamin, RNAiMAX (Ambion, Invitrogen Dynal, Oslo, Norway) and TLR3-siRNA (sense-GAACUGGAUAUCUUUGCATT, antisense-UGGCAAAGAUAUCCAGUUCTT) (5nM) or a non-silencing control (SenseUUCUCCGAACGUGUCACGUdTdT, Antisense-ACGUGACACGUUCGGAGAAdTdT) (5nM) (both from Qiagen, Sollentuna, Sweden). The cells were incubated at 37°C and 5%
CO2 for 24h before they were stimulated with poly(I:C) (5ug/ml) for 20h. Supernatant was collected and kept at -20°C until CXCL10 content was determined by ELISA, while remaining cells were either assayed by MTT assay, or washed and lysed and stored at -80ºC until total cellular RNA was isolated for qRT-PCR. siRNA knockdown of TLR3 was confirmed by qRT-PCR in HT-29 cells after TLR3 siRNA transfection and poly-IC stimulation.
RNA isolation and qRT-PCR
Total cellular RNA was isolated from lysed cells using Ambion mirVana miRNA isolation kit (Ambion, Austin, TX) according to the manufacturer's protocol. RNA was quantified using a NanoDrop ND-1000 Spectrophotometer (Saveen Werner AB, Malmö, Sweden 
CXCL10 and hsCRP in serum.
CXCL10 in serum was quantified using ELISA as described for the studies on intestinal epithelial cells. hsCRP analyses were done with a commercially available immunoturbidometric assay (Tina-quant, Roche, Indianapolis, IN).
Stimulation of PBMCs.
PBMCs from 39 randomly chosen subjects (control=9, UC=10, CD=10, UC+PSC=10)
were thawed. No one used corticosteroids or other immunosuppressive medication at the time of sampling (Table 2) PBMCs was analysed in supernatant by ELISA as described for IEC stimulation. PBMCs from 5 healthy donors were isolated as in the patient material, but not frozen, and CXCL10
was quantified in the supernatants.
Statistical Analysis
Microarray data analysis was done using Bioconductor (8) in the R software environment. Differential expression was determined using linear models with least squares regression and empirical Bayes moderated t-statistics (9) . P-values were adjusted for multiple comparisons using Benjamini Hochberg false discovery rate correction. The Kruskal-Wallis test was used for analysis of differences in levels of proteins in supernatant and serum. If significance, the Mann-Whitney U-test was used to test differences between pairs of subjects.
For correlation between protein serum levels the Spearman Rank Correlation test was used.
Fischer test was used to evaluate differences in immunohistochemical staining between groups. Calculations were performed by PASW Statistics version 18. A difference was considered significant if p<0.05 (2-sided).
Results
Clinical material
The 133 biopsies enrolled in the microarray analysis were sampled from 112 subjects (Table 1) . Altogether 21 subjects with IBD had two biopsies taken; one from an area of active and one from inactive disease. Five of the subjects included in UC group also have associated PSC. There were no differences in age, duration of disease between the patient groups. The difference found regarding medication is as expected according to clinical practice, with more patients with UC receiving 5-ASA/S-ASA as compared to CD patients and more patients with CD receiving systemic corticosteroids compared to UC patients.
CXCL10 and CXCR3 are overexpressed in biopsies from active UC and active CD.
Microarray gene expression analysis showed a significant overexpression of CXCL10 and CXCR3 mRNAs in active UC and CD, both when compared to healthy controls and to nondiseased mucosa from UC or CD patients (Fig. 1A) . Average CXCL10 mRNA change in diseased UC mucosa vs healthy controls was, log2, 2.58 (fold change 5.98), and diseased CD mucosa vs healthy controls, log2, 2.25 (fold change 4.76). CXCR3 changes were more modest but significant, log2, 0.39 (fold change 1.31) for UC vs healthy controls, and log2, 0.54 (fold change 1.45) for CD. In biopsies from nondiseased mucosa from UC and CD patients we found no significant change in CXCL10 or CXCR3 expression compared to healthy controls.
The mRNAs of the cytokines IL1β, CXCL8, TNFα and IFNγ were also overexpressed in active UC and active CD vs controls and non-inflamed UC/CD, so also CXCL9 and CXCL11 (Fig. 1B) . Strong correlations were found when comparing the mRNA levels of CXCL10 and CXCR3 to the proinflammatory cytokines IL1β, CXCL8, TNFα and IFNγ and also the chemokines CXCL 9 and CXCL11 (Table 2) .
Colonic epithelial cells are an important source of CXCL10
Representative results from immunohistochemical examination of CXCL10 and CXCR3 in diseased mucosa of UC and CD patients and also controls are shown in Fig. 2 . and NOD2 in addition to cytokines IL10 and IL1b (Table 3 ). The TLR3-ligand poly(I:C) induced a massive CXCL10 release (Fig.3) . No other ligands induced release of CXCL10 in these cells. MTT assay was done on both cell lines and viability was not influenced by any of the ligands used.
To ensure the CXCL10 release was mediated via TLR3, siRNA transfection of HT-29 cells was done and TLR3 levels analysed using quantitative RT-PCR. The CXCL10 release following transfection was reduced by 50.0% compared to non-transfected poly(I:C) stimulated HT-29 cells (Fig. 4) . The TLR3 mRNA level, using qRT-PCR, was profoundly upregulated (218.4 %) after poly(I:C) stimulation and knockdown of TLR3 by siRNA transfection reduced its mRNA abundance by 87.7% ( siRNA TLR3 vs siRNA control). MTT assay shows preserved viability of cells independent of transfection reagent / siRNA.
CXCL10 release in PBMC.
We explored the CXCL10 release from PBMCs upon PRR-ligand stimulation using the same ligands as in the intestinal epithelial cell lines. PBMCs from 39 randomly chosen subjects were assayed; controls (n=9), UC (n=10), UC +PSC (n=10) and CD (n=10) ( Table   4 ). There was a significant difference in use of 5-ASA/sulphasalazine between UC and CD patients which reflects clinical practice, however there was no significant difference in constitutive CXCL10 release from PBMCs whether these drugs were used or not.
Following a 6-hour-stimulation of PBMCs, we analyzed the supernatant using the Bio-Plex assay as described. We found a constitutive CXCL10 release from PBMCs. Moreover, the nucleic acid ligands poly(I:C) (TLR3), R848 (TLR 7/8), and CpG (TLR9) considerably induced CXCL10 release in PBMCs after 6 hours stimulation in both controls (Fig. 5) and IBD patients. However, we could not find any differences in CXCL10 release between controls and UC or CD when assessing these four CXCL10 inducing ligands. Interestingly, the constitutive release of CXCL10 from PBMCs was inversely correlated with the serum levels of CXCL10 in IBD patients, p=0.013, rho=-0.396 The same response pattern, regarding induction of CXCL10 release, was found in freshly isolated PBMCs from five healthy controls, showing that cryopreservation of PBMC did not influence these cellular responses.
CXCL10 in serum showed a considerable inter-individual variability. There was no significant difference in CXCL10 levels between patient groups, other than a trend towards a higher level in UC patients with PSC as compared to healthy controls and to UC patients without PSC (both p=0.080).
Discussion
The initial microarray gene expression analyses described in this study were done on endoscopic biopsies from a large, well controlled IBD biobank collected in a routine clinical setting. Assessing the results to generate hypotheses on the inflammatory processes in IBD, we observed a marked and highly significant increase in mRNA abundance of CXCL10 in endoscopic biopsies from diseased mucosa. Moreover, although to a lesser degree, its receptor CXCR3 was also upregulated. The mRNA levels of CXCL10 and CXCR3 were strongly correlated and they also correlate very well to other, more established markers of inflammation such as IL1β, CXCL8, and TNFα in inflamed mucosa, supporting that CXCL10
indeed has a role in the inflammatory process in IBD.
CXCL10 is known to be expressed in monocytes, fibroblasts, endothelium (10) and also in intestinal epithelial cells (11) , thus the overexpression of CXCL10 in mucosal biopsies can derive from both epithelial, stromal and immune cells. Although somewhat controversial, the immune cells of the colonic mucosa have earlier been considered the main source of CXCL10It has, however, also been shown that IFNγ and to a lesser degree IL1β and TNFα induce CXCL10 release from epithelial cells (11, 12) . In our immunohistochemical studies (Fig. 2) , the CXCL10 protein is localized mainly to the intestinal epithelium. CXCL10 positivity is clearly higher in inflamed UC and CD mucosa, as compared to healthy control individuals, and like mRNA abundance it is similarly increased in the two diseases. This points to the colonic epithelium as an important source of chemokine attracting CXCR3+
cells. In addition to the cytoplasmatic staining we see dense granula in relation to the nucleus.
One previous study on keratinocytes reports granulas of CXCL10 located to the rough endoplasmatic reticulum (13) . This finding is interpreted as a sign of de novo synthesis of CXCL10 in the colonic epithelial cells.
There are few studies on CXCL10 in the colonic mucosa of IBD patients, and these results seem somewhat inconsistent. One study (14) A paradigm in IBD pathogenesis has been that UC is characterized by an atypical Th2 inflammation and CD by an inflammation where Th1 cytokines dominate (2, 3). CXCL10 is considered as a chemokine that supports Th1-type inflammation and antagonizes Th2-type inflammation (18) . Thus, the observation of a marked and similar increase of CXCL10 in both UC and CD is surprising. This supports the emerging view that separation of IBD into Th1/Th2 inflammation is to rigid, and that UC and CD show features characteristic of both types of inflammation. This suggestion is supported by the finding of overexpressed IFNγ (the classic Th1-cytokine) in our clinical material of IBD. IFNγ causes release of CXCL10 from several cell types (19) . We found CXCL10 and IFNγ to be upregulated in both active UC and CD, IFNγ and CXCL10 correlating well. This analysis does not allow us to discern whether the primary event is induction of CXCL10 by IFNγ, or of the increase of IFNγ is seen as a result of IFNγ producing CXCR3+ cells influx as response to TLR3-mediated CXCL10 release.
CXCR3+ is mainly expressed on activated Th1-cells and also found on memory Tcells, NK cells, B-cells, mast cells and endothelial cells (18) . There are inconsistent data about expression of CXCR3 in mucosa of active IBD (20, 21) . Previous studies using immunohistochemical staining found an increased number of CXCR3+ cells in submucosa of CD but not in lamina propria, and not in UC patients (21) . In this study we found CXCR3 mRNA to be, although highly significant, only modestly overexpressed in both UC and CD.
We could, however, not find any difference in the number of CXCR3+ cells in mucosa of active IBD vs inactive IBD or controls. This may be due to internalization of receptor when arriving at the site of inflammation (22) Supporting the role of the CXCL10/ CXCR3 axis in IBD are observations suggesting that it may be involved in the pathogenesis of several other chronic inflammatory diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis and atherosclerosis (27) . In Tables: CXCL10 release from HT-29 (A) and SW620 (C) cells stimulated with PRR-ligands corresponding to TLR1-9 and NOD2 (see Table 3 CXCL10 release from PBMCs in healthy controls stimulated with PRR-ligands corresponding to TLR1-9 and NOD2 or the cytokines IL10 and IL1β (see Table 3 ) for 6h. Cell supernatant was harvested and assayed for CXCL10 by muliplexing. Highest observed value in range at 42000 pg/mL indicated by ____. 9 of 9 values for poly(I:C) were above range. 6 of 9 values for R848 were above range. Data given as mean ± SEM.
Figure legends
The supernatant was diluted 1:10 and analysed using ELISA CXCL10 for the ligands poly(I:C) and R848 showing 5 times higher CXCL10 release in poly(I:C) stimulated HT-29 comparing R848 stimulated HT-29 (data not shown). 
